Gary MD - Verrica Pharmaceuticals Chief Officer
| VRCA Stock | USD 0.99 0.01 1.00% |
Insider
Gary MD is Chief Officer of Verrica Pharmaceuticals
| Age | 47 |
| Address | 44 West Gay Street, West Chester, PA, United States, 19380 |
| Phone | 484 453 3300 |
| Web | https://www.verrica.com |
Verrica Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.7141) % which means that it has lost $0.7141 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.5989) %, meaning that it created substantial loss on money invested by shareholders. Verrica Pharmaceuticals' management efficiency ratios could be used to measure how well Verrica Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.86. In addition to that, Return On Capital Employed is expected to decline to -1.07. At present, Verrica Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3.9 M, whereas Total Assets are forecasted to decline to about 62 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Anne McKay | Fennec Pharmaceuticals | 70 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Bhaskar Chaudhuri | Arcutis Biotherapeutics | 69 | |
| Scott Burrows | Arcutis Biotherapeutics | 47 | |
| David MD | Nuvation Bio | 54 | |
| David Osborne | Arcutis Biotherapeutics | 63 | |
| JeanPaul MD | Inventiva Sa | N/A | |
| Jens Okkels | Ascendis Pharma AS | 63 | |
| Kevin Capps | Crinetics Pharmaceuticals | N/A | |
| Francis Conway | Larimar Therapeutics | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| Patricia Turney | Arcutis Biotherapeutics | 57 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Charles Maggs | Vigil Neuroscience | N/A | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| David Hanley | Nuvation Bio | 54 | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Birgitte MD | Ascendis Pharma AS | 62 | |
Management Performance
| Return On Equity | -20.6 | ||||
| Return On Asset | -0.71 |
Verrica Pharmaceuticals Leadership Team
Elected by the shareholders, the Verrica Pharmaceuticals' board of directors comprises two types of representatives: Verrica Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Verrica. The board's role is to monitor Verrica Pharmaceuticals' management team and ensure that shareholders' interests are well served. Verrica Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Verrica Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eugene Scavola, Executive Operations | ||
| Terence Kohler, Chief Officer | ||
| Dr MBA, Head Development | ||
| Christopher Hayes, Secretary, Officer | ||
| Joe Bonaccorso, Chief Commercial Officer | ||
| Gary MD, Chief Officer | ||
| Ted White, President CEO, Director | ||
| John CPA, Interim CFO |
Verrica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Verrica Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.6 | ||||
| Return On Asset | -0.71 | ||||
| Operating Margin | 11.62 % | ||||
| Current Valuation | 113.9 M | ||||
| Shares Outstanding | 45.6 M | ||||
| Shares Owned By Insiders | 16.20 % | ||||
| Shares Owned By Institutions | 16.42 % | ||||
| Number Of Shares Shorted | 4.37 M | ||||
| Price To Book | 238.54 X | ||||
| Price To Sales | 4.91 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.